Dataset Information

Comparison of colistin-induced nephrotoxicity between two different formulations of colistin in critically ill patients: a retrospective cohort study.

ABSTRACT:

Background

Colistin is widely used in the treatment of nosocomial infections caused by carbapenem-resistant gram-negative bacilli (CR-GNB). Colistin-induced nephrotoxicity is one of the major adverse reactions during colistin treatment. Comparisons of colistin-induced nephrotoxicity between different formulations of colistin are rarely reported.

Methods

In this retrospective cohort study, we enrolled intensive care unit-admitted patients if they had culture isolates of CR-GNB and underwent intravenous treatment with colistin. The occurrence of acute kidney injury (AKI) during intravenous treatment with colistin was recorded. The occurrence of colistin-induced nephrotoxicity was compared between two formulations of colistin, Locolin®, and Colimycin®. Treatment outcomes associated with the occurrence of colistin-induced nephrotoxicity were also investigated.

Results

Among 195 patients, 95 who were treated with Locolin® and 100 who were treated with Colimycin® were included for analysis. Patients treated with Locolin® had a higher rate of occurrence of stage 2 (46.3% vs. 32%, p = 0.040) and stage 3 (29.5% vs. 13%, p = 0.005) AKI than did those treated with Colimycin®. In multivariate analysis, the presence of septic shock (adjusted odds ratio [aOR] 2.17, 95% confidence interval [CI] 1.10-4.26) and inappropriate colistin dosage (aOR 2.52, 95% CI 1.00-6.33) were clinical factors associated with colistin-induced nephrotoxicity. Treatment with Colimycin® was an independent factor associated with a lower risk of colistin-induced nephrotoxicity (aOR 0.37, 95% CI 0.18-0.77). The mortality rate was comparable between patients with and without colistin-induced nephrotoxicity.

Conclusions

The risk of colistin-induced nephrotoxicity significantly varied in different formulations of colistin in critically ill patients. Colistin-induced nephrotoxicity was not associated with increased mortality rate.

SUBMITTER: Feng JY

PROVIDER: S-EPMC8323087 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Comparison of colistin-induced nephrotoxicity between two different formulations of colistin in critically ill patients: a retrospective cohort study.

Feng Jia-Yih JY Lee Yi-Tzu YT Pan Sheng-Wei SW Yang Kuang-Yao KY Chen Yuh-Min YM Yen David Hung-Tsang DH Li Szu-Yuan SY Wang Fu-Der FD

Antimicrobial resistance and infection control 20210730 1

<h4>Background</h4>Colistin is widely used in the treatment of nosocomial infections caused by carbapenem-resistant gram-negative bacilli (CR-GNB). Colistin-induced nephrotoxicity is one of the major adverse reactions during colistin treatment. Comparisons of colistin-induced nephrotoxicity between different formulations of colistin are rarely reported.<h4>Methods</h4>In this retrospective cohort study, we enrolled intensive care unit-admitted patients if they had culture isolates of CR-GNB and ...[more]

PMID: 34330333

Similar Datasets

Project description:Background/Objectives: Aciclovir is a widely used antiviral agent. Since aciclovir is primarily eliminated through the kidneys, maintaining renal function is crucial to avoid toxicity. Although mitigating strategies are introduced in the standard of care, nephrotoxicity is still a major concern during treatment, especially for critically ill intensive care unit (ICU) patients. Therefore, risk factors for the development of nephrotoxicity during aciclovir therapy should be addressed. This study aimed to evaluate if aciclovir in combination with therapeutic drug monitoring (TDM) and additional nephrotoxicity-mitigating strategies is associated with a decrease in renal function in critically ill ICU patients. Methods: In a cohort of ICU patients with or without intravenous aciclovir treatment (including standard of care mitigating strategies) propensity score matching was applied to balance baseline characteristics between aciclovir-treated and untreated groups. Aciclovir was monitored by measuring serum levels and the dose was adjusted when needed. Renal function was primarily assessed through serum creatinine. Univariate and multivariate regression analyses were used to identify risk factors for nephrotoxicity during ICU admission. Results: After propensity score matching, the study included 518 ICU patients, of whom 259 received aciclovir. Aciclovir was not associated with a significant decrease in renal function during admission. In fact, renal function appeared to improve in the aciclovir-treated group compared to the control group (beta-coefficient: -14.5 (95% confidence interval: -28.3 to -0.68), p = 0.04). Median aciclovir concentrations remained within the exploratory therapeutic range. Conclusions: Aciclovir therapy, at least when appropriately monitored, does not independently induce nephrotoxicity in critically ill ICU patients. TDM may further enhance safety by preventing supratherapeutic drug exposures. The results are significant as they provide evidence supporting the safe use of aciclovir in a vulnerable patient population. Future studies should focus on establishing therapeutic and toxic concentration thresholds for aciclovir and assessing the clinical utility of TDM in this context.

Project description:BackgroundMobilisation and exercise intervention in general are safe and feasible in critically ill patients. For patients requiring catecholamines, however, doses of norepinephrine safe for mobilisation in the intensive care unit (ICU) are not defined. This study aimed to describe mobilisation practice in our hospital and identify doses of norepinephrine that allowed a safe mobilisation.MethodsWe conducted a retrospective single-centre cohort study of 16 ICUs at a university hospital in Germany with patients admitted between March 2018 and November 2021. Data were collected from our patient data management system. We analysed the effect of norepinephrine on level (ICU Mobility Scale) and frequency (units per day) of mobilisation, early mobilisation (within 72 h of ICU admission), mortality, and rate of adverse events. Data were extracted from free-text mobilisation entries using supervised machine learning (support vector machine). Statistical analyses were done using (generalised) linear (mixed-effect) models, as well as chi-square tests and ANOVAs.ResultsA total of 12,462 patients were analysed in this study. They received a total of 59,415 mobilisation units. Of these patients, 842 (6.8%) received mobilisation under continuous norepinephrine administration. Norepinephrine administration was negatively associated with the frequency of mobilisation (adjusted difference -0.07 mobilisations per day; 95% CI - 0.09, - 0.05; p ≤ 0.001) and early mobilisation (adjusted OR 0.83; 95% CI 0.76, 0.90; p ≤ 0.001), while a higher norepinephrine dose corresponded to a lower chance to be mobilised out-of-bed (adjusted OR 0.01; 95% CI 0.00, 0.04; p ≤ 0.001). Mobilisation with norepinephrine did not significantly affect mortality (p > 0.1). Higher compared to lower doses of norepinephrine did not lead to a significant increase in adverse events in our practice (p > 0.1). We identified that mobilisation was safe with up to 0.20 µg/kg/min norepinephrine for out-of-bed (IMS ≥ 2) and 0.33 µg/kg/min for in-bed (IMS 0-1) mobilisation.ConclusionsMobilisation with norepinephrine can be done safely when considering the status of the patient and safety guidelines. We demonstrated that safe mobilisation was possible with norepinephrine doses up to 0.20 µg/kg/min for out-of-bed (IMS ≥ 2) and 0.33 µg/kg/min for in-bed (IMS 0-1) mobilisation.

Project description:IntroductionVancomycin is widely used to treat infections caused by Gram positive bacteria, mostly methicillin-resistant strains. Despite its therapeutic effectiveness, vancomycin is a nephrotoxic drug that has been associated with the occurrence of acute kidney injury (AKI). In this study, we sought to evaluate the variability of serum trough concentrations of vancomycin and to determine the incidence and risk factors of vancomycin-associated nephrotoxicity (VAN) in non-critically ill patients.MethodsThis was a prospective cohort including Brazilian public hospital inpatients from April 2017 to June 2018. The participants received intravenous vancomycin therapy for at least 48 hours for any suspected or confirmed infection by Gram positive bacteria. Demographic, clinical and laboratory data were collected. Information on vancomycin therapy and concomitant use of other nephrotoxic drugs were also recorded. Patients were followed up until discontinuation of vancomycin treatment or death, whatever occurred first. The primary outcome was the occurrence of AKI. We performed a Poisson regression to determine risk factors for AKI.ResultsOverall, 98 participants were included in the study. Median age was 55.9 (interquartile range [IQR] 40.6-66.8) years and 58 (59.2%) were men. Most of them showed subtherapeutic (<10mg/L) or supratherapeutic (>20mg/L) trough levels of vancomycin; 42.9% and 15.3%, respectively. A total of 19 (19.4%) patients developed AKI. Poisson regression showed that male sex (odds ratio [OR] 2.90; confidence interval [CI] 95% 1.28-6.53; p = 0.011), concomitant use of piperacillin-tazobactam (OR 4.66; CI 95% 2.26-9.58; p <0.001) and vancomycin trough levels above 20mg/mL (OR 4.21; CI 95% 1.57-11.278; p = 0.004) were independently associated with AKI.ConclusionsOur study showed that usual doses of vancomycin did not reach recommended therapeutic serum trough levels of vancomycin in non-critically ill patients. Besides that, nephrotoxicity was common in this population, being associated with male sex, concomitant use of piperacillin-tazobactam and supra-therapeutic trough serum levels of vancomycin.

Dataset Information

Comparison of colistin-induced nephrotoxicity between two different formulations of colistin in critically ill patients: a retrospective cohort study.

Background

Methods

Results

Conclusions

Publications

Comparison of colistin-induced nephrotoxicity between two different formulations of colistin in critically ill patients: a retrospective cohort study.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets